22UA:FRA
BioNTech SE - ADR
€85.40
arrow_downward
-0.93%(-0.80) 1D
Oct 2, 10:00:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€85.75
High
€86.90
Low
€85.30
Mkt. cap
24.34B
Avg. vol.
917.00
Volume
22.56K
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
Open
€85.75
High
€86.90
Low
€85.30
Mkt. cap
24.34B
Avg. vol.
917.00
Volume
22.56K
52-wk high
€105.50
52-wk low
€68.00
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
14 hours ago
BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading
AD HOC NEWS
·
19 hours ago
BioNTech's Founders Sell Shares and Face Fresh Patent Suits as German Plants Wind Down
AD HOC NEWS
·
1 day ago
Morgan Stanley sets USD 115 target for BioNTech stock
AD HOC NEWS
·
2 days ago
BioNTech stock after-hours at EUR 87.00: plus 0.29 percent
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR